Core Viewpoint - Huajian Medical has transformed from an IVD distributor to a "medical innovation drug chain investment bank" within 18 days, driven by a series of strategic actions and market enthusiasm, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD [1][7]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a supporting stablecoin, IVDDollar (IVDD) [4]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was completed on July 20, with applications for stablecoin licenses submitted to the SEC and CFTC [4]. - From July 23 to 28, the company executed three high-priced buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [4]. - On July 29, the subsidiary Weida secured a multi-million HKD revolving loan led by East Asia Bank, showcasing financial institutions' endorsement of the company's development [4]. - A brand strategy upgrade was announced on July 30, with a new logo and a redefined brand essence of "Innovation-Verification-Development" [4]. - The same day, a partnership was formed with BGI's CoWin to establish an innovative drug intellectual property tokenization fund, facilitating the last mile of medical asset blockchain integration [4]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [8]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [8]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [8]. Group 3: Valuation Revolution - Following the announcement of the dual listing on July 14, Huajian Medical's stock price began a rapid ascent, with a cumulative increase of 75.1% from July 14 to 21 [9]. - On July 31, the stock price peaked at 4.99 HKD, marking a 15.78% increase for the day, and pushing the market capitalization to 8 billion HKD [9]. - The company's valuation is shifting from a traditional IVD distributor's sales multiple to an ecological premium associated with the medical RWA exchange [9]. Group 4: Future Outlook - Huajian Medical aims to become a leader in the medical RWA sector, akin to NASDAQ for medical asset tokenization, Visa for stablecoin payment scenarios, and Apple for integrating technology, assets, and capital into a closed loop [12]. - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa in 2024 [10]. - The company's strategy involves creating a closed-loop ecosystem that captures innovative drug pipelines, facilitates RWA tokenization, and enables payment settlements through IVDD stablecoin [10].
华检医疗的“疯狂7月”